Brokerages Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) PT at $751.00

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $751.00.

IDXX has been the topic of a number of recent research reports. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. UBS Group decreased their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th.

IDEXX Laboratories Stock Up 0.9%

IDXX stock opened at $544.32 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market capitalization of $42.94 billion, a P/E ratio of 40.08, a P/E/G ratio of 2.95 and a beta of 1.55. IDEXX Laboratories has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The business has a 50-day moving average of $556.27 and a 200-day moving average of $595.41.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories will post 14.68 earnings per share for the current fiscal year.

Institutional Trading of IDEXX Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Beacon Investment Advisory Services Inc. increased its holdings in IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after buying an additional 6,710 shares during the last quarter. Nordea Investment Management AB lifted its stake in IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after acquiring an additional 8,845 shares during the last quarter. Diversified Trust Co. lifted its stake in IDEXX Laboratories by 223.5% in the fourth quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after acquiring an additional 2,901 shares during the last quarter. Congress Asset Management Co. grew its position in shares of IDEXX Laboratories by 9,894.0% in the 4th quarter. Congress Asset Management Co. now owns 153,908 shares of the company’s stock valued at $104,123,000 after acquiring an additional 152,368 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in shares of IDEXX Laboratories by 13.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 43,469 shares of the company’s stock valued at $29,408,000 after acquiring an additional 5,215 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.